A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Microsatellite instability-high (MSI-H) is a biomarker for response to immune checkpoint inhibitors (ICIs). Approximately one-third of endometrial cancers (ECs) exhibit an MSI-H phenotype.1Hause R.J. Pritchard C.C. Shendure J. Salipante S.J. Classification and characterization of microsatellite instability across 18 cancer types.Nat Med. 2016; 22: 1342-1350Crossref PubMed Scopus (406) Google Scholar However, these neoplasms originate from...